The myopia epidemic continues to pose a significant international challenge, but the eye care community has made strides in reducing its progression in pediatric patients.
In September 2025, the FDA granted market authorization to Essilor Stellest spectacle lenses (EssilorLuxottica), the first eyeglasses capable of slowing pediatric progression. With the glasses now available in the U.S., Healio | OSN Pediatrics/Strabismus Board Members, led by Section Editor Robert S. Gold, MD, sat down to discuss how patients and their families have responded to the lenses in the real world: Has the price of